On July 14, 2026, Apotex received FDA approval for ANDA 210725, positioning the company to enter the [Insert Substance] market immediately following the introduction of the reference listed drug. The timing of this new generic entry is expected to significantly impact pricing and drive volume for the [Insert Substance] class.